MX2015006356A - Formulacion de capsula de acido 5-aminosalicilico. - Google Patents

Formulacion de capsula de acido 5-aminosalicilico.

Info

Publication number
MX2015006356A
MX2015006356A MX2015006356A MX2015006356A MX2015006356A MX 2015006356 A MX2015006356 A MX 2015006356A MX 2015006356 A MX2015006356 A MX 2015006356A MX 2015006356 A MX2015006356 A MX 2015006356A MX 2015006356 A MX2015006356 A MX 2015006356A
Authority
MX
Mexico
Prior art keywords
aminosalicylic acid
capsule formulation
acid capsule
tablets
salt
Prior art date
Application number
MX2015006356A
Other languages
English (en)
Other versions
MX361275B (es
Inventor
Emma Boyd
Deborah Leigh Caldwell
Catherine Coulter
Ryan Loughlin
Stephem Mccullagh
Original Assignee
Warner Chilcott Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50588745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015006356(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Chilcott Co Llc filed Critical Warner Chilcott Co Llc
Publication of MX2015006356A publication Critical patent/MX2015006356A/es
Publication of MX361275B publication Critical patent/MX361275B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una forma de dosificación que comprende una cápsula que contiene una o más tabletas de ácido 5-aminosalicílico o una sal del mismo como un ingrediente activo en donde cada una de una o más tabletas es entéricamente recubierta.
MX2015006356A 2012-11-21 2013-11-19 Formulacion de capsula de acido 5-aminosalicilico. MX361275B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/683,080 US20140141075A1 (en) 2012-11-21 2012-11-21 5-aminosalicylic acid capsule formulation
PCT/IB2013/003125 WO2014091308A1 (en) 2012-11-21 2013-11-19 5-aminosalicylic acid capsule formulation

Publications (2)

Publication Number Publication Date
MX2015006356A true MX2015006356A (es) 2016-03-16
MX361275B MX361275B (es) 2018-12-03

Family

ID=50588745

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006356A MX361275B (es) 2012-11-21 2013-11-19 Formulacion de capsula de acido 5-aminosalicilico.

Country Status (10)

Country Link
US (3) US20140141075A1 (es)
EP (1) EP2922532B1 (es)
CN (1) CN105209023A (es)
AR (1) AR094634A1 (es)
AU (1) AU2013356926B2 (es)
CA (1) CA2891638A1 (es)
IL (1) IL238790B (es)
MX (1) MX361275B (es)
SG (1) SG11201504012XA (es)
WO (1) WO2014091308A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210236519A1 (en) * 2020-01-30 2021-08-05 Atoz Pharmaceuticals Pvt Ltd Controlled release dosage forms of 5-aminosalicylic acid and process thereof
US20220125733A1 (en) * 2020-10-23 2022-04-28 Atoz Pharmaceuticals Pvt Ltd Nongranulated compressed tablets of mesalamine, and process of preparation thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
GB2253346A (en) 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
US5733575A (en) 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
JP3670016B2 (ja) 1994-12-16 2005-07-13 ワーナー−ランバート・カンパニー カプレットをカプセル内に封入する方法及びかかる方法により得ることができる固体剤形
US6245350B1 (en) 1994-12-16 2001-06-12 Warner-Lambert Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
WO2000018377A1 (en) * 1998-09-28 2000-04-06 Warner-Lambert Company Enteric and colonic delivery using hpmc capsules
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
JP3716901B2 (ja) 1999-04-14 2005-11-16 シオノギクオリカプス株式会社 セルロースエーテルフィルム
US6420473B1 (en) 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US20030096001A1 (en) 2000-06-06 2003-05-22 Cherukuri S. Rao Encapsulation products and method of controlled release of fluoxetine or mesalamine
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
IT1318625B1 (it) 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
WO2002017887A1 (de) 2000-08-29 2002-03-07 Mepha Ag Arzneimittel zur behandlung von darmerkrankungen
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
WO2003045356A1 (en) * 2000-11-20 2003-06-05 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings
DE10208335A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
ATE482694T1 (de) 2002-07-05 2010-10-15 Temrel Ltd Zusammensetzung zur kontrollierten wirkstoffabgabe
DE602004007315D1 (de) * 2003-03-03 2007-08-16 Personnes A Responsibilite Lim Stabilisierte pharmazeutische Zusammensetzung enthaltend einen NSAID und einen Prostaglandin
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
BRPI0417985A (pt) 2003-12-23 2007-04-17 Temrel Ltd uso de água para controlar o tamanho de partìculas, e, processo para a produção de partìculas para uso em uma composição farmacêutica
KR101123001B1 (ko) 2004-09-01 2012-03-13 더 프록터 앤드 갬블 캄파니 5-아미노-2-하이드록시벤조산 및 환원당을 함유하는 조성물
US20080020041A1 (en) 2004-10-19 2008-01-24 Ayres James W Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
US20090017110A1 (en) * 2005-05-31 2009-01-15 Capricorn Pharma Inc. Modified release formulations of anti-irritability drugs
US7964215B1 (en) 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
EP2012756A4 (en) 2006-04-20 2013-01-23 Inventia Healthcare Private Ltd MULTI-UNIT COMPOSITIONS
US20090036414A1 (en) 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
HUE034848T2 (en) 2008-01-10 2018-03-28 Evonik Roehm Gmbh Coated pharmaceutical or nutritional composition with improved drug release in the colon
EA022886B1 (ru) 2008-10-03 2016-03-31 Др. Фальк Фарма Гмбх Способ поддержания ремиссии язвенного колита у пациентов
US20120093939A1 (en) 2008-12-17 2012-04-19 Altheus Therapeutics, Inc. Oral formulations
DK3045043T3 (da) * 2009-02-26 2020-08-03 Relmada Therapeutics Inc Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
BRPI0924427A2 (pt) 2009-03-18 2016-01-26 Evonik Roehm Gmbh composição farmacêutica de liberação controlada, seu processo de preparação e uso da mesma
IT1395143B1 (it) 2009-08-06 2012-09-05 Sofar Spa Composizioni granulari a rilascio controllato di mesalazina e processo per il loro ottenimento.
US9463163B2 (en) 2009-10-16 2016-10-11 Sun Pharmaceutical Industries Limited Delayed release pharmaceutical composition of mesalamine
EP2340812A1 (en) 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
AU2011224350B2 (en) 2010-03-09 2015-07-02 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
EP2425826A1 (en) 2010-09-01 2012-03-07 Disphar International B.V. Mesalazine tablet having improved dissolution
JP6566638B2 (ja) * 2012-03-07 2019-08-28 サンタラス， インコーポレイテッドＳａｎｔａｒｕｓ，Ｉｎｃ． メサラミンの放出制御固形製剤
EP3187171A1 (en) * 2012-04-30 2017-07-05 Tillotts Pharma AG A delayed release drug formulation
AU2013266857B2 (en) 2012-05-19 2016-02-11 Dr. Falk Pharma Gmbh Compositions and methods for treatment of irritable bowel syndrome with 5-aminosalicylate

Also Published As

Publication number Publication date
US20140370083A1 (en) 2014-12-18
US10265273B2 (en) 2019-04-23
WO2014091308A1 (en) 2014-06-19
CN105209023A (zh) 2015-12-30
US10688057B2 (en) 2020-06-23
SG11201504012XA (en) 2015-06-29
AU2013356926A1 (en) 2015-06-11
AR094634A1 (es) 2015-08-19
US20140141075A1 (en) 2014-05-22
MX361275B (es) 2018-12-03
US20190201348A1 (en) 2019-07-04
IL238790B (en) 2019-12-31
EP2922532B1 (en) 2019-03-06
AU2013356926B2 (en) 2018-07-05
CA2891638A1 (en) 2014-06-19
IL238790A0 (en) 2015-06-30
EP2922532A1 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
IL238713A0 (en) Self-regulating active pharmaceutical ingredient release
GEP20207102B (en) Sulfonamides as modulators of sodium channels
EP3256149A4 (en) FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS
SG11201406141UA (en) Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient
MX351584B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
MY163083A (en) Solid forms of a pharmaceutically active substance
IN2015DN03984A (es)
EP2823819A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING OLEANOLIC ACID ACETATE AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF MEDIATED DISEASE BY TLR OR IL-6
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX340188B (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
PH12014501408A1 (en) Immediate release multi unit pellet system
BR112017004948A2 (pt) formulação farmacêutica.
IL260766B (en) Continuous production of complexes containing active pharmaceutical ingredients
WO2012074830A3 (en) Modified release tranexamic acid formulation
IL262059A (en) A layer coated tablet with high chemical stability of the active ingredient
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
MX2015006356A (es) Formulacion de capsula de acido 5-aminosalicilico.
IL236466B (en) Pharmaceutical composition for the release of active components
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
EP2452678A3 (en) Pulsatile-release pharmaceutical formulation of dexlansoprazole
EP2886112A4 (en) COMPOSITION CONTAINING AS ACTIVE INGREDIENT OF S-ALLYL-L-CYSTEINE FOR PREVENTING OR TREATING OCULAR DISEASES, AND PHARMACEUTICAL FORMULATION COMPRISING THE SAME
HUP1000444A2 (en) Process for the preparation of a pharmaceutical active ingredient
TR201007926A1 (tr) Prasugrel tablet formülasyonları.
GB201216893D0 (en) Drug substance preparations, pharmaceutical compositions and dosage forms comprising s-(+)-flurbiprofen
PL2678006T3 (pl) Pakowanie stałych preparatów farmaceutycznych zawierających substancję aktywną triazotan glicerolu

Legal Events

Date Code Title Description
FG Grant or registration